eCite Digital Repository
Technology evaluation: MRA, Chugai
Citation
Ding, C and Jones, G, Technology evaluation: MRA, Chugai, Current Opinion in Molecular Therapeutics, 5, (1) pp. 64-9. ISSN 1464-8431 (2003) [Professional, Non Refereed Article]
Abstract
Chugai, the Japanese subsidiary of Roche, is developing a humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.
Item Details
| Item Type: | Professional, Non Refereed Article |
|---|---|
| Research Division: | Biomedical and Clinical Sciences |
| Research Group: | Pharmacology and pharmaceutical sciences |
| Research Field: | Clinical pharmacology and therapeutics |
| Objective Division: | Health |
| Objective Group: | Clinical health |
| Objective Field: | Clinical health not elsewhere classified |
| UTAS Author: | Ding, C (Professor Chang-Hai Ding) |
| UTAS Author: | Jones, G (Professor Graeme Jones) |
| ID Code: | 28591 |
| Year Published: | 2003 |
| Web of Science® Times Cited: | 15 |
| Deposited By: | Menzies Centre |
| Deposited On: | 2003-08-01 |
| Last Modified: | 2004-03-15 |
| Downloads: | 0 |
Repository Staff Only: item control page